Sanuwave Q3 Revenue Drops 24% as CMS Rule Freezes Ultramist Demand
SNWV is trading near its 52-week low of $1.75 (7.4% above the low).
Summary
Revenue fell 24% to $8.6 million from $11.3 million a year ago, and the company swung to a $1.1 million operating loss from $0.9 million of operating income. The damage is concentrated in hardware: only 40 Ultramist systems sold versus 155 a year ago and 82 last quarter, while recurring applicator revenue actually rose 2% to $6.9 million. CEO Morgan Frank pinned the collapse on the CMS proposed rule — mobile wound care practices, especially rural home care, exited operations, customers took a wait-and-see stance on the 97610 code, and a used-equipment market cannibalized new unit sales. Adjusted EBITDA fell to $0.7 million from $3.2 million, and cash dropped to $6.6 million from $11.9 million at year-end, including $2.3 million paid out on sales tax voluntary disclosure agreements. This lands on top of a September Nasdaq delisting notice over the $50 million market value requirement and an October JPMorgan covenant waiver, so the balance sheet and listing status are already under pressure. A business update call is scheduled for November 11 at 8:30 a.m. EST.
At the time of this announcement, SNWV was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.2M. The 52-week trading range was $1.75 to $36.20. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.